Pharmaceutical News

RSS

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Eli Lilly and Company and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

16 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

American Biotech launches new silver hydrogel wound-dressing products

American Biotech Labs, LLC, is pleased to announce the availability of three new silver hydrogel wound-dressing products.

16 Sep 2014

Patients with particular genetic variation more prone to drug-induced pancreatitis

Doctors have discovered that patients with a particular genetic variation are four times more likely to develop pancreatitis if they are prescribed a widely used group of drugs.

16 Sep 2014

Benefits of blood pressure lowering drugs for low risk patients 'still open to question'

Dr Stephen Martin and colleagues argue that this strategy is failing patients and wasting healthcare resources. They call for a re-examination of the threshold and urge clinicians to be cautious about treating low risk patients with blood pressure lowering drugs.

16 Sep 2014

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today.

16 Sep 2014

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle three insect-borne diseases-malaria, dengue and Chagas disease.

16 Sep 2014

Study: High-dose prescribing increases by 23% in Canada

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new research.

15 Sep 2014

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.

15 Sep 2014

People who take antidepressants are twice as likely to have dental implants fail

A team from McGill University has discovered that people who take the most common antidepressants (such as Celexa, Paxil, Lexapro, Prozac, and Zoloft, the Selective Serotonin Reuptake Inhibitors or SSRIs) are twice as likely to have dental implants fail as those who are not taking SSRIs.

12 Sep 2014

ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited.

11 Sep 2014

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners.

11 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

The Centers for Disease Control and Prevention (CDC) and Premier, Inc. have released new research on the widespread use of unnecessary and duplicative antibiotics in U.S. hospitals, which could have led to an estimated $163 million in excess costs.

11 Sep 2014

New research shows statins could reduce common diabetes complications

The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology.

11 Sep 2014

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.

10 Sep 2014

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness.

10 Sep 2014

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above.

10 Sep 2014

Pharmaceuticals against malaria can now be produced from waste of plant-extraction

Research success through collaborative efforts of chemists and engineers from Berlin/Potsdam and Magdeburg. All of the best currently available pharmaceuticals against malaria can now be produced in pure form using a single process, even from the waste of the plant-extraction.

10 Sep 2014

Pharmaceutical News

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

American Biotech launches new silver hydrogel wound-dressing products

Patients with particular genetic variation more prone to drug-induced pancreatitis

Benefits of blood pressure lowering drugs for low risk patients 'still open to question'

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

Study: High-dose prescribing increases by 23% in Canada

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

People who take antidepressants are twice as likely to have dental implants fail

ChromaDex signs NIAGEN supply agreement with Healthy Directions

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

FDA approves Contrave extended-release tablets for chronic weight management

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

New research shows statins could reduce common diabetes complications

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Now, women experiencing morning sickness can benefit from Diclegis drug

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

Pharmaceuticals against malaria can now be produced from waste of plant-extraction

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News